Published in Blood Weekly, September 8th, 2005
"We report long-term results of treatment of myelodysplastic syndrome (MDS) with erythropoietin and G-CSF. A total of 129 patients were followed up 45 months after last inclusion in the Nordic MDS Group studies," scientists in Sweden reported.
"Erythroid response rate was 39% and median response duration 23 months (range, 3-116 months or more). Complete responders showed longer response duration than partial responders (29 versus 12 months, p=.006). The International Prognostic Scoring System (IPSS) groups...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.